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Background: We report the case of a patient who had a non-functional metastatic pancreatic neuroendocrine
tumour (pNET), which changed in functionality during the course of the disease. This case demonstrates the
effectiveness of conventional cytotoxic chemotherapy in the management of select group of patients with this rare,
challenging condition.
Case presentation: Our patient was a 34 year old man under oncology follow up, diagnosed with a non-functional
metastatic pancreatic neuroendocrine tumour treated with a Whipple’s procedure two years ago. Despite treatment
with somatostatin analogues and sunitinib, a tyrosine kinase inhibitor, he had demonstrated radiological progression
of his metastatic disease. He now presented with a short history of Cushing’s syndrome. A presumptive diagnosis of a
rapidly progressive, metastatic, functional pNET with ectopic ACTH production was made, confirmed biochemically and
with liver biopsy. The proliferative index, Ki-67 of 20% of the liver biopsy prompted us to treat him with conventional
cytotoxic chemotherapy using streptozocin, 5-fluorouracil and doxorubicin. Prior to its administration clinical and
biochemical control of the hypercortisolemic state was achieved with metyrapone. However the clinical, biochemical
and radiological response to chemotherapy was so dramatic obviating the need for metyrapone therapy.
Conclusions: Non-functional pNETs may evolve in their clinical and biologic behaviour producing functional hormonal
syndromes. Chemotherapy may be an effective therapeutic modality in such circumstances.
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ACTH secretion in functional pNETS is rare and it is
even more rare for non-functional pNETs to evolve into
ACTH secreting functional tumours with only very few
cases reported in literature. We describe such an inter-
esting and rare case of evolution in functionality of a
non-functional pNET. Apart from control of hypercorti-
solaemic state, preventing disease progression can be a
real challenge despite various therapeutic modalities be-
ing increasingly used in the last decade. We report the
case of a young patient who had a non-functional pNET,* Correspondence: daniel.cuthbertson@liverpool.ac.uk
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unless otherwise stated.which later started secreting ACTH, highlighting the im-
portance of being very vigilant during the follow up of
such patients. Despite novel chemotherapeutic options
and PRRT (Peptide Receptor Radionuclide Therapy), con-
ventional chemotherapeutic agents still have a very im-
portant role and should be tried if the above agents fail to
control disease state as demonstrated by our case.Case presentation
We report the case of a 34-year-old man who presented
with a one-month history of lethargy, generalised upper
and lower limb weakness and significant weight gain. He
had been recently diagnosed with type 2 diabetes melli-
tus and initiated on pre-mixed insulin injections 30 units
twice daily (HbA1c 85 mmol/mol).Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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Figure 1 (upper figure) 111Indium-labeled Octreotide scan.
Figure 1 (lower figure) Ki-67 immunostaining of liver metastasis
(at recurrence) showing a high proliferative rate of 20%.
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crine tumour (pNET) two years previously, having pre-
sented with jaundice and abdominal pain. An abdominal
CT had demonstrated tumour in the head of the pancreas
with loco-regional metastases (peripancreatic lymph nodes
and nine hepatic metastatic lesions varying in size from
7–18 mm) for which he underwent a Whipple’s procedure
with resection of lymph nodes and an intra-operative liver
biopsy. Measurement of a full fasting gut hormone profile
showed elevated chromogranin A but was otherwise nor-
mal, consistent with a non-functional tumour. Immuno-
histochemistry of the pancreatic specimen was positive for
chromogranin and synaptophysin with a Ki-67 index of
2% confirming the diagnosis of a Grade 2 pNET (ACTH
staining not performed); the liver biopsy appearances
were similar morphologically. A careful family history of
endocrine tumours or endocrine disorders had been
unremarkable.
On follow up imaging he had developed further liver
metastases, so was commenced on a long-acting som-
atostatin analogue (Lanreotide), for its anti-proliferative
potential, and a tyrosine kinase inhibitor (Sunitinib) was
thereafter added upon evidence of further radiological
progression.
Two years subsequently, he presented with cushingoid
features with a moon face, easy bruising, abdominal
striae, centripetal fat distribution and marked proximal
myopathy. Blood pressure was normal. Biochemical in-
vestigations revealed serum potassium concentration of
2.5 mmol/l, glucose 17 mmol/l and significantly elevated
random serum cortisol of 2003 nmol/L and serum
ACTH concentration 50 pmol/L (normal range 2–11
pmol/L). Basal pituitary biochemistry and gadolinium
enhanced MRI imaging was otherwise unremarkable.
MRI scan of the liver revealed solid and cystic metastatic
deposits ranging between 7.8-9.2 cm in segments 6, 7 and
8 indicating further progression despite sunitinib.111In-
labeled octreotide scanning demonstrated somatostatin
receptor positive disease in five of his liver metastatic
deposits but not in any other sites (Figure 1).
A diagnosis of a rapidly progressive, functional, metastatic
pNET with ectopic ACTH production causing Cushing’s
syndrome was made, with an assumption that the tumour
had evolved in its functionality from its previous non-
functional status. Treatment options discussed at the
supra-regional multidisciplinary team meeting (ENETS
Centre of Excellence) considered metyrapone, bilateral
adrenalectomy, peptide receptor radionuclide therapy
(PRRT) or cytotoxic chemotherapy. Mutational analysis
of the gene for multiple endocrine neoplasia type 1
(MEN 1) was negative.
A repeat liver biopsy was performed to provide an ac-
curate histological grade of the liver metastases, on the
premise that primary NETs, and their synchronous/metachronous metastases, frequently differ in grade and
proliferative index (Ki-67). Immunohistochemistry was
strongly positive for chromogranin and synaptophysin
with a Ki-67 index of 20% (ACTH staining not performed)
(Figure 1). The treatment decision based on this result
was to administer conventional cytotoxic chemotherapy
with streptozocin, 5-fluorouracil and doxorubicin, with
metyrapone given pre-chemotherapy to control the hyper-
cortisolaemic state. Incremental doses of metyrapone
(up to 1 g qds) effected a dramatic clinical response (with
resolution of his symptoms and reduction of his insulin
dosage) and an equally dramatic biochemical response
(normalisation of serum potassium and lowering of mean
cortisol concentrations on cortisol day curves) prior to his
chemotherapy.
Three months after starting his chemotherapy, he had
managed to completely discontinue his metyrapone with
excellent mean cortisol concentrations on his cortisol day
curve of 315 nmol/L (Figure 2 graph), with serum ACTH
concentration of 11pmol/l. He discontinued all insulin
injections with excellent glycaemic control (HbA1c
53 mmol/mol) and cross-sectional imaging (abdominal
CT) showing a dramatic reduction in the size of the hep-
atic metastases with more necrotic/cystic contents than
previously. He remains clinically stable three months later.
Rajeev et al. BMC Endocrine Disorders 2014, 14:70 Page 3 of 4
http://www.biomedcentral.com/1472-6823/14/70Discussion
pNETs are rare with a reported incidence of 1-2/100,000.
They may be functional tumours, with an associated clinical
syndrome, or non-functional, which despite not producing
any hormone-specific symptoms, frequently either secrete
other peptides (such as pancreatic polypeptide, chromogra-
nin A, neuron specific enolase) or may stain positively on
immunohistochemistry for certain hormones.
The most common functional pancreatic NET syn-
dromes relate to insulinoma and gastrinoma. ACTH se-
cretion occurs only rarely, presenting with features of
Cushing’s syndrome, but more than 95% are malignant
with an average age at diagnosis of 50–55 years and an
equal sex distribution [1]. Functional pNETs account for
4-16% of patients with ectopic ACTH secretion [1]. The
diagnostic approach is similar to that in suspected Cushing’s
syndrome, first to confirm excess cortisol production and
then to localise the tumour source.
Even more rarely, initially non-functional pNETs have
been reported to evolve into functional tumours. In a
series of 353 patients described by Wynick et al., 24 pa-
tients demonstrated de novo evidence of secretion of a
second hormone during the course of the disease (me-
dian delay of 19 months and 92% reflecting liver metas-
tases) [2]. Several reports have highlighted clinical cases
of ectopic ACTH/Cushing’s syndrome, where secondary
deposits stained strongly positive for ACTH despite a
primary tumour being negative on ACTH staining [3].
In our case, ACTH staining was not deemed necessary
with biochemical confirmation, considering the high cost
involved and availability of ACTH staining in only a sin-
gle United Kingdom centre. However, as above, our pa-
tient presented after 24 months of the initial diagnosis of
non-functional pNET with hepatic metastatic disease
and de novo Cushing’s syndrome, highlighting evolution
in tumour functionality should be considered during fol-
low up of patients with pNETs.Figure 2 Cortisol day curves demonstrating cortisol
concentrations on incremental doses of metyrapone, up to 1 g
qds prior to chemotherapy, and effects of chemotherapy with
patient having discontinued metyrapone.Treatment aims are twofold involving biochemical
control of hypercortisolaemia and preventing disease
progression. Adrenal blocking agents like metyrapone,
or bilateral adrenalectomy in patients who fail to re-
spond to metyrapone therapy, may be used to address
hypercortisolaemia. Medical treatment of the neuroen-
docrine tumour may involve long acting somatostatin
analogues (SSA) or occasionally alpha interferon may be
effective. Surgery is recommended even in the presence
of metastatic disease, including localized liver metasta-
ses, if potentially resectable, and symptomatic control of
the hormone excess state through cytoreductive surgery
or radiofrequency ablation. However, our patient had
large, multiple liver metastatic deposits and hence sur-
gery was not deemed to be an option.
In patients with advanced, surgically non-resectable,
progressive pNETs, everolimus [4] and sunitinib [5] are
novel chemotherapeutic options and PRRT (Peptide Recep-
tor Radionuclide Therapy) may also have a role. Ki-67 index
is important in deciding treatment options and triage
patients into the most appropriate treatment arm. Con-
ventional chemotherapy with streptozocin, 5- fluorouarcil
and doxorubicin still has a place as in the manage-
ment of some patients with more aggressive tumours.
Our patient failed to respond to SSAs and sunitinib,
but had an excellent treatment response to conven-
tional chemotherapy.Conclusions
This clinical case offers several important learning points.
Firstly, there should be vigilance to the possibility of an
evolution or change of functionality of pNETs, during
tumour progression, particularly in non-functional pNETs
considering their pluripotency with awareness of the vari-
ous clinical syndromes that may arise. Secondly, repeat
histological examination of metastatic deposits may indi-
cate different biological behaviour of the tumour and this
may modify the treatment regime. In the case described,
we observed the evolution towards Cushing’s syndrome
from a non-functional tumour, with repeat histological
findings modifying our treatment approach and facilitating
effective treatment with chemotherapy. The different pro-
liferative potential may represent inherent heterogeneity
within the tumour or across different anatomical sites but
may reflect evolution in the histology towards a higher
grade.Consent
Written informed consent was obtained from the patient
for publication of this Case report and any accompany-
ing images. A copy of the written consent is available for
review by the Editor of this journal.
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